

ILLUMINA INC.

ISIN: US4523271090 WKN: 452327109 Asset Class: Stock

Company

2021/02/24 22:00:00



Price
461.05
USD

Difference  **-0.75%(-3.49)**



Contact Details

ILLUMINA INC. Tel: +1-858-202-4500
 Juliet Cunningham Fax: +1-858-202-4545
 Illumina Way 5200 Web: <http://www.illumina.com/>
 92122 San Diego, California E-mail: ir@illumina.com

Company Profile

Illumina is improving human health by unlocking the power of the genome. The company's focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Illumina's products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments.

Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2020		2019		2018	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	4,483,000,000		4,451,000,000		4,490,000,000	
Common stock capital		2,000,000		2,000,000		2,000,000
Fixed assets	-		-		-	
Equity capital of a company		4,694,000,000		4,613,000,000		3,845,000,000
Cash and cash equivalents	1,810,000,000		2,042,000,000		1,144,000,000	
Accrued liabilities		-		516,000,000		513,000,000
Other assets	-		-		-	
Current liabilities		1,244,000,000		665,000,000		1,804,000,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		-		-		-
Different income		-		-		-
Other liabilities		-		-		-
Total assets	7,585,000,000	7,585,000,000	7,316,000,000	7,316,000,000	6,959,000,000	6,959,000,000

Balance notes

	2020	2019	2018
Accounting standard	US-GAAP	US-GAAP	US-GAAP
Employees	7,800	7,700	7,300
Equity ratio	61.89%	63.05%	56.50%
Debt-equity ratio	61.59%	58.60%	76.98%

Others

	2020	2019	2018
Tax Expense Rate	23.36%	11.45%	12.53%

ILLUMINA INC.

ISIN: US4523271090 WKN: 452327109 Asset Class: Stock

Income statement

	2020	2019	2018
Turnover	3,239,000,000	3,543,000,000	3,333,000,000
Net income	656,000,000	1,002,000,000	826,000,000
EBIT	706,456,800	903,703,500	748,547,100
Operating income before taxes	856,000,000	1,118,000,000	894,000,000
Cash Flow	1,080,000,000	1,051,000,000	1,142,000,000
Net interest income	-	23,000,000	-13,000,000
Research and development expenses	682,000,000	647,000,000	623,000,000
Income taxes	200,000,000	128,000,000	112,000,000
Result from investments in subsidiaries, associates and other	-	-	-
Revenues per employee	342,711	379,745	376,812

Board of Directors**Members of Management Board**

Jay T. Flatley	Chairman of Board of Directors
Susan E. Siegel	Member of Board of Directors
Scott Gottlieb	Member of Board of Directors
Robert S. Epstein	Member of Board of Directors
Philip W. Schiller	Member of Board of Directors
John W. Thompson	Member of Board of Directors
Gary S. Guthart	Member of Board of Directors
Francis A. deSouza	Member of Board of Directors
Caroline Dorsa	Member of Board of Directors
Frances Arnold	Member of Board of Directors
Francis deSouza	Chairman of Managing Board
Susan Tousi	Member of Executive Committee
Sam A. Samad	Member of Executive Committee
Paula Dowdy	Member of Executive Committee
Nicole Berry	Member of Executive Committee
Mark Van Oene	Member of Executive Committee
Li Qing	Member of Executive Committee
Kathryne Reeves	Member of Executive Committee
Juliet Cunningham	Member of Executive Committee
Jacque Ross	Member of Executive Committee